Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25221931 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL17387673 | 0.85 | CYP3A4 (0.43) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL2419398 | 0.85 | CYP3A4 (0.43) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL24741970 | 0.82 | NPC1 (0.50) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL4712988 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL25346203 | 0.82 | SMN1; SMN2 (0.33) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL24742033 | 0.77 | CYP3A4 (0.36) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL31503458 | 0.76 | CYP3A4 (0.38) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL24741784 | 0.76 | CYP3A4 (0.38) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL29207594 | 0.76 | CYP3A4 (0.38) | SMN1; SMN2NPC1LMNATP53PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321042-A1 | COMBINATION THERAPY | PFIZER INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11773082-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11718603-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-08-08 | — | — | US | disclosed |
| WO-2023092107-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-4181919-A1 | COMBINATION THERAPY | Pfizer Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| WO-2023083201-A1 | AMINOPYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海拓界生物医药科技有限公司 | 2023-05-19 | — | — | WO | disclosed |
| EP-3917913-A2 | 3-CARBONYLAMINO-5-CYCLOPENTYL-1H-PYRAZOLE COMPOUNDS HAVING INHIBITORY ACTIVITY ON CDK2 | Pfizer Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| US-11014911-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2021-05-25 | — | — | US | disclosed |
| WO-2020157652-A2 | CDK2 INHIBITORS | PFIZER INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20200247784-A1 | CDK2 INHIBITORS | PFIZER INC. (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247784-A1 | CDK2 INHIBITORS | CDK2, CDK1, CCNI | SMN1; SMN2 1988/4885NPC1 3325/4885LMNA 1764/4885 |
| US-11773082-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | SMN1; SMN2 1988/4885NPC1 3325/4885LMNA 1764/4885 |
| US-11718603-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | SMN1; SMN2 1988/4885NPC1 3325/4885LMNA 1764/4885 |
| US-20230321042-A1 | COMBINATION THERAPY | CDK4, CDK6, CDK2 | SMN1; SMN2 3370/4885NPC1 4116/4885LMNA 3075/4885 |
| US-11014911-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | SMN1; SMN2 1988/4885NPC1 3325/4885LMNA 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.